15:27 , Jun 8, 2018 |  BC Week In Review  |  Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated...
20:58 , Jun 7, 2018 |  BC Extra  |  Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Oxford BioMedica, Sanofi deal

The companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and UshStat for all ocular disease indications in exchange for the return to Oxford of all worldwide rights to EncorStat...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

StarGen: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

RetinoStat: Phase I ongoing

Oxford BioMedica said FDA and France's National Agency for the Safety of Medicine and Health Products (ANSM) agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat and a...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

RetinoStat: Phase I suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

StarGen: Phase I/IIa suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

UshStat: Phase I/IIa suspended enrollment

Oxford BioMedica suspended enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat after detecting "very low" concentrations of potential impurities in clinical trial material. The company believes the...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

StarGen: Interim Phase I/IIa data

Oxford BioMedica and partner Sanofi reported interim data from 8 patients with Stargardt's disease in the first cohort of an open-label, dose-escalation, international Phase I/IIa trial showing that StarGen led to no serious adverse events...